{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T00:27:10Z","timestamp":1786753630689,"version":"build-2736575974"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,10]]},"DOI":"10.1097\/iae.0b013e31818358b2","type":"journal-article","created":{"date-parts":[[2008,10,6]],"date-time":"2008-10-06T03:12:50Z","timestamp":1223262770000},"page":"1308-1313","source":"Crossref","is-referenced-by-count":71,"title":["CHANGES IN AQUEOUS VASCULAR ENDOTHELIAL GROWTH FACTOR AND PIGMENT EPITHELIAL-DERIVED FACTOR LEVELS FOLLOWING INTRAVITREAL BEVACIZUMAB INJECTIONS FOR CHOROIDAL NEOVASCULARIZATION SECONDARY TO AGE-RELATED MACULAR DEGENERATION OR PATHOLOGIC MYOPIA"],"prefix":"10.1097","volume":"28","author":[{"given":"WAI-MAN","family":"CHAN","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"TIMOTHY Y.Y.","family":"LAI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KWOK-PING","family":"CHAN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HAITAO","family":"LI","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DAVID T.L.","family":"LIU","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"DENNIS S.C.","family":"LAM","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"CHI-PUI","family":"PANG","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-21-20210130","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.ajo.2003.09.042","article-title":"Choroidal neovascularization.","volume":"137","author":"Grossniklaus","year":"2004","journal-title":"Am J Ophthalmol"},{"key":"R2-21-20210130","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/S0161-6420(96)30515-0","article-title":"Etiology of choroidal neovascularization in young patients.","volume":"103","author":"Cohen","year":"1996","journal-title":"Ophthalmology"},{"key":"R3-21-20210130","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S0161-6420(01)00544-9","article-title":"Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin: 1-year results of a randomized clinical trial\u2014VIP report no. 1.","volume":"108","year":"2001","journal-title":"Ophthalmology"},{"key":"R4-21-20210130","first-page":"198","article-title":"Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials\u2014TAP report 2.","volume":"119","author":"Bressler","year":"2001","journal-title":"Arch Ophthalmol"},{"key":"R5-21-20210130","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/jcp.10026","article-title":"Novel mechanism for age-related macular degeneration: an equilibrium shift between the angiogenesis factors VEGF and PEDF.","volume":"189","author":"Ohno-Matsui","year":"2001","journal-title":"J Cell Physiol"},{"key":"R6-21-20210130","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.clinbiochem.2005.11.013","article-title":"Contribution of VEGF and PEDF to choroidal angiogenesis: a need for balanced expressions.","volume":"39","author":"Tong","year":"2006","journal-title":"Clin Biochem"},{"key":"R7-21-20210130","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ajo.2005.10.012","article-title":"Aqueous humor levels of vascular endothelial growth factor and pigment epithelium-derived factor in polypodial choroidal vasculopathy and choroidal neovascularization.","volume":"141","author":"Tong","year":"2006","journal-title":"Am J Ophthalmol"},{"key":"R8-21-20210130","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/S0014-5793(01)02110-X","article-title":"Unbalanced expression of VEGF and PEDF in ischemia-induced retinal neovascularization.","volume":"489","author":"Gao","year":"2001","journal-title":"FEBS Lett"},{"key":"R9-21-20210130","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1126\/science.285.5425.245","article-title":"Pigment epithelium-derived factor: a potent inhibitor of angiogenesis.","volume":"285","author":"Dawson","year":"1999","journal-title":"Science"},{"key":"R10-21-20210130","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.ophtha.2005.11.019","article-title":"Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.","volume":"113","author":"Avery","year":"2006","journal-title":"Ophthalmology"},{"key":"R11-21-20210130","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/01.iae.0000238561.99283.0e","article-title":"Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration.","volume":"26","author":"Spaide","year":"2006","journal-title":"Retina"},{"key":"R12-21-20210130","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1097\/01.iae.0000225766.75009.3a","article-title":"Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.","volume":"26","author":"Rich","year":"2006","journal-title":"Retina"},{"key":"R13-21-20210130","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration.","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N Engl J Med"},{"key":"R14-21-20210130","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJMoa062655","article-title":"Ranibizumab versus verteporfin for neovascular age-related macular degeneration.","volume":"355","author":"Brown","year":"2006","journal-title":"N Engl J Med"},{"key":"R15-21-20210130","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1136\/bjo.2006.096776","article-title":"Intravitreal bevacizumab (Avastin) as treatment for subfoveal choroidal neovascularisation secondary to pathological myopia.","volume":"91","author":"Yamamoto","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"R16-21-20210130","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1136\/bjo.2006.099887","article-title":"Intravitreal injection of bevacizumab for choroidal neovascularisation associated with pathological myopia.","volume":"91","author":"Sakaguchi","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"R17-21-20210130","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1016\/j.ophtha.2007.03.043","article-title":"Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularization: 6-month results of a prospective pilot study.","volume":"114","author":"Chan","year":"2007","journal-title":"Ophthalmology"},{"key":"R18-21-20210130","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1001\/archopht.125.10.1363","article-title":"Vascular endothelial growth factor in aqueous humor before and after intravitreal injection of bevacizumab in eyes with diabetic retinopathy.","volume":"125","author":"Sawada","year":"2007","journal-title":"Arch Ophthalmol"},{"key":"R19-21-20210130","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1136\/bjo.2003.032466","article-title":"Expression of pigment epithelium derived factor and vascular endothelial growth factor in choroidal neovascular membranes and polypoidal choroidal vasculopathy.","volume":"88","author":"Matsuoka","year":"2004","journal-title":"Br J Ophthalmol"},{"key":"R20-21-20210130","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ajo.2006.01.085","article-title":"Expression of VEGF and PEDF in choroidal neovascular membranes following verteporfin photodynamic therapy.","volume":"142","author":"Tatar","year":"2006","journal-title":"Am J Ophthalmol"},{"key":"R21-21-20210130","first-page":"1490","article-title":"Effects of triamcinolone on the expression of VEGF and PEDF in human retinal pigment epithelial and human umbilical vein endothelial cells.","volume":"12","author":"Tong","year":"2006","journal-title":"Mol Vis"},{"key":"R22-21-20210130","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00417-004-0950-7","article-title":"Aqueous humor levels of cytokines are related to vitreous levels and progression of diabetic retinopathy in diabetic patients.","volume":"243","author":"Funatsu","year":"2005","journal-title":"Graefes Arch Clin Exp Ophthalmol"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00006982-200810000-00021","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:13:04Z","timestamp":1786036384000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00006982-200810000-00021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,10]]},"references-count":22,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2008]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0b013e31818358b2","relation":{},"ISSN":["0275-004X"],"issn-type":[{"value":"0275-004X","type":"print"}],"subject":[],"published":{"date-parts":[[2008,10]]}}}